AzTrials
AzTrials

Study AdherenceNCT04513080

Message-Based Psychotherapy and Digital Treatment Sequences for Depression

A study testing Video-Chat Psychotherapy (VCP), Message-Based Psychotherapy (MBP) and Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy in people with Study Adherence and Depressive Disorder, run by Talkspace at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This partnership between Talkspace and the University of Washington (UW) ALACRITY Center will determine how effective unlimited text-based psychotherapy for depression is when compared to once-a-week psychotherapy. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Study Adherence, Depressive Disorder
What is being tested?
Video-Chat Psychotherapy (VCP), Message-Based Psychotherapy (MBP) and Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,184 participants
Where
1 siteUnited States
Study dates
2 Mar 2020to 14 Jan 2024
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 18 years old or older
  • English or Spanish speaking
  • Live in the United States
  • Score of 10 or greater on the Patient Health Questionnaire-9 (PHQ-9) screening
  • Receive a diagnosis of depression from a Talkspace intake clinician

Who cannot join

  • Under the age of 18
  • Non-English or Spanish speaking
  • Do not meet criteria for a depressive disorder
  • Participants with active suicidal ideation or with a primary diagnosis of psychosis will also be excluded and referred to intensive care.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Talkspace

    New York, New York, 10025

Other trials in United States

About this study

This partnership between Talkspace and the University of Washington (UW) ALACRITY Center will determine how effective unlimited text-based psychotherapy for depression is when compared to once-a-week psychotherapy. This study will also determine what the best treatment options are for people who are not responding well to either unlimited texting or weekly psychotherapy. The results of this study will be a new product version of message-based care that can tailor psychotherapy intensity based on the needs of future consumers with depression.

Read the detailed description

This is a fast track Small Business Innovation Research (SBIR) proposal that will (1) test the effectiveness of daily, message-based psychotherapy (MBP) for depression, compared to traditionally delivered, video-chat psychotherapy (VCP) and (2) develop an evidence-based treatment sequence for those who do not respond to either daily MBP or VCP.

Phase 1 consists of a pilot study to determine the best incentive model to retain a sample of people 18 years old and older with depression into a SMART trial. Information from this pilot will inform the retention strategy for Phase 2.

Phase 2 is a 12-week, randomized clinical trial using a SMART design to test the following aims: 1. Determine the relative effectiveness of daily MBP compared to weekly VCP in treating symptoms of depression and improving social functioning; 2. For those who fail to respond to 6 weeks of weekly VCP only, determine whether the addition of daily messaging, or a switch to monthly video-chat plus daily messaging improves depression and functional outcomes; and 3. For those who fail to respond to 6 weeks of daily MBP, whether the addition of monthly video-chat or weekly video-chat improves outcomes. Participants will provide data on mood, activity, and functioning, and we will collect data on use of treatment (texts and sessions), and working alliance.

Being tested
Video-Chat Psychotherapy (VCP), Message-Based Psychotherapy (MBP), Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy, Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy, High Monetary Incentive (HMI)
Medical subject headings
Depressive Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Video-Chat Psychotherapy (VCP)Behavioural

    Video-Chat Psychotherapy (VCP) consists of weekly psychotherapy appointments that last between 30-45 minutes. These sessions are conducted using Agora, a secure, HIPAA-compliant video conferencing service that is seamlessly integrated into the Talkspace platform application. Therapists will provide evidence-based treatments for depression and anxiety.

  • Message-Based Psychotherapy (MBP)Behavioural

    Message-Based Psychotherapy (MBP) allows patients to chat with an assigned licensed therapist as frequently as they wish. After consumers complete an intake and select a therapist, the consumer can begin chatting with their therapist right away, and as often as they wish. Therapists respond to text within 15 minutes to an hour during office hours, and within 14 hours outside of office hours. Thus, MBP is not fully synchronous. This enables therapists to deliver care to a larger number of patients than is possible under synchronous methods by disentangling the therapist's time from the patient's time to respond. It also has the potential to improve quality as it gives the therapist time to think through the most effective response and intervention. MBP will be based on CBT, PST or IPT intervention strategies.

  • Message-Based Psychotherapy with Monthly Video-Chat PsychotherapyBehavioural

    Message-Based Psychotherapy (MBP) with monthly Video-Chat Psychotherapy (VCP) allows patients unlimited texting with their therapist and once a month, 30-45 minute video chat with the same therapist. Therapist and participants schedule their video chat appointment to occur at once a month interval during therapist office hours. The content of these sessions, as well as the MBP portion of care, will be based on CBT, PST or IPT. In Phase 1, this is referred to as "Switch Arm" (for participants assigned to VCP at baseline) or "Minimal Augmentation" (for participants assigned to MBP at baseline). In Phase 2, this is referred to as the "Premium Plan".

  • Message-Based Psychotherapy with Weekly Video-Chat PsychotherapyBehavioural

    Message-Based Psychotherapy (MBP) with weekly Video-Chat Psychotherapy (VCP) allows patients access to both unlimited MBP, but will be able to schedule weekly, 30-45 minute video chat with the same therapist. Therapists will provide care based on CBT, PST or IPT. In Phase 1, this is referred to as the "Augmentation Arm". In Phase 2, this is referred to as the "Ultimate Plan."

  • High Monetary Incentive (HMI)Behavioural

    Participants in the traditional, high monetary incentive arm will receive a total of $125 for completing 12 weeks of assessments.

  • Low Monetary and Alternative Incentive (LMAI)Behavioural

    Participants in the Low Monetary and Alternative Incentive (LMAI) arm received a total of $75 for completing 12 weeks of assessments, messages of encouragement for completing daily assessments, and weekly texts showing participants their clinical improvement and assessment completion rate.

Study groups in NCT04513080
Study groupRoleWhat they receive
Phase 2: Message-Based Psychotherapy (MBP; Level 1 and Level 2)ExperimentalPhase 2 participants who respond to Message-Based Psychotherapy (MBP; Level 1) by 5 weeks of care will continue in this condition from weeks 6 to 12 (MBP; Level 2).
Receives: Behavioral: Message-Based Psychotherapy (MBP)
Phase 2: Video-Chat Psychotherapy (VCP; Level 1 and Level 2)ExperimentalPhase 2 participants who respond to Video-Chat Psychotherapy (VCP; Level 1) by 5 weeks of care will continue in this condition from weeks 6 to 12 (VCP; Level 2). VCP consists of weekly psychotherapy appointments that last between 30-45 minutes.
Receives: Behavioral: Video-Chat Psychotherapy (VCP)
Phase 2: MBP (Level 1) to Premium Plan (MBP with monthly VCP; Level 2)ExperimentalPhase 2: This arm includes participants in MBP (Level 1) who do not respond to treatment by week 5. The Premium Plan intervention consists of MBP with monthly VCP (Level 2). The Premium Plan allows patients unlimited MBP and once a month, 30-45 minute video chat with the same therapist. This intervention will serve as one of two Level 2 conditions for participants who do not respond to MBP or VCP alone by week 5.
Receives: Behavioral: Message-Based Psychotherapy (MBP); Behavioral: Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy
Phase 2: MBP (Level 1) to Ultimate Plan (MBP with weekly VCP; Level 2)ExperimentalPhase 2: This arm includes participants in MBP (Level 1) who do not respond to treatment by week 5. The Ultimate Plan intervention consists of MBP with weekly VCP (Level 2). The Ultimate Plan allows patients unlimited MBP and weekly, 30-45 minute video chat with the same therapist. This intervention will serve as one of two Level 2 conditions for participants who do not respond to MBP or VCP alone by week 5.
Receives: Behavioral: Message-Based Psychotherapy (MBP); Behavioral: Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy
Phase 2: VCP (Level 1) to Premium Plan (MBP with monthly VCP; Level 2)ExperimentalPhase 2: This arm includes participants in VCP (Level 1) who do not respond to treatment by week 5. The Premium Plan intervention consists of MBP with monthly VCP (Level 2). The Premium Plan allows patients unlimited MBP and once a month, 30-45 minute video chat with the same therapist. This intervention will serve as one of two Level 2 conditions for participants who do not respond to MBP or VCP alone by week 5.
Receives: Behavioral: Video-Chat Psychotherapy (VCP); Behavioral: Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy
Phase 2: VCP (Level 1) to Ultimate Plan (MBP with weekly VCP; Level 2)ExperimentalPhase 2: This arm includes participants in VCP (Level 1) who do not respond to treatment by week 5. The Ultimate Plan intervention consists of MBP with weekly VCP (Level 2). The Ultimate Plan allows patients unlimited MBP and weekly, 30-45 minute video chat with the same therapist. This intervention will serve as one of two Level 2 conditions for participants who do not respond to MBP or VCP alone by week 5.
Receives: Behavioral: Video-Chat Psychotherapy (VCP); Behavioral: Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy
Phase 1: High Monetary Incentive (HMI) + VCP (Level 1 and Level 2)ExperimentalPhase 1 participants who respond to VCP (Level 1) by 5 weeks of care will continue in this condition from weeks 6 to 12 (VCP; Level 2). Participants in the High Monetary Incentive (HMI) arm received a total of $125 for completing 12 weeks of assessments.
Receives: Behavioral: Video-Chat Psychotherapy (VCP); Behavioral: High Monetary Incentive (HMI)
Phase 1: High Monetary Incentive (HMI) + MBP (Level 1 and Level 2)ExperimentalPhase 1 participants who respond to MBP (Level 1) by 5 weeks of care will continue in this condition from weeks 6 to 12 (MBP; Level 2). Participants in the High Monetary Incentive (HMI) arm received a total of $125 for completing 12 weeks of assessments.
Receives: Behavioral: Message-Based Psychotherapy (MBP); Behavioral: High Monetary Incentive (HMI)
Phase 1: Low Monetary and Alternative Incentive (LMAI) + VCP (Level 1 and Level 2)ExperimentalPhase 1 participants who respond to VCP (Level 1) by 5 weeks of care will continue in this condition from weeks 6 to 12 (VCP; Level 2). Participants in the Low Monetary and Alternative Incentive (LMAI) arm received a total of $75 for completing 12 weeks of assessments, messages of encouragement for completing daily assessments, and weekly texts showing participants their clinical improvement and assessment completion rate.
Receives: Behavioral: Video-Chat Psychotherapy (VCP); Behavioral: Low Monetary and Alternative Incentive (LMAI)
Phase 1: Low Monetary and Alternative Incentive (LMAI) + MBP (Level 1 and Level 2)ExperimentalPhase 1 participants who respond to MBP (Level 1) by 5 weeks of care will continue in this condition from weeks 6 to 12 (MBP; Level 2). Participants in the Low Monetary and Alternative Incentive (LMAI) arm received a total of $75 for completing 12 weeks of assessments, messages of encouragement for completing daily assessments, and weekly texts showing participants their clinical improvement and assessment completion rate.
Receives: Behavioral: Message-Based Psychotherapy (MBP); Behavioral: Low Monetary and Alternative Incentive (LMAI)
Phase 1: HMI + VCP (Level 1) to Augmentation Arm (MBP with weekly VCP; Level 2)ExperimentalPhase 1: This arm includes participants in HMI + VCP (Level 1) who do not respond to treatment by week 5. The Augmentation Arm consists of MBP with weekly VCP (Level 2). Participants will have access to unlimited MBP and will be able to schedule weekly, 30-45 minute video chat with the same therapist. This intervention will serve as one of two conditions for participants who do not respond to MBP or VCP alone by week 5.
Receives: Behavioral: Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy; Behavioral: High Monetary Incentive (HMI)
Phase 1: HMI + VCP (Level 1) to Switch Arm (MBP with monthly VCP; Level 2)ExperimentalPhase 1: This arm includes participants in HMI + VCP (Level 1) who do not respond to treatment by week 5. The Switch Arm consists of MBP with monthly VCP (Level 2). Patients have access to unlimited MBP and once a month, 30-45 minute video chat with the same therapist. This intervention will serve as one of two conditions for participants who do not respond to MBP or VCP alone by week 5.
Receives: Behavioral: Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy; Behavioral: High Monetary Incentive (HMI)
Phase 1: HMI + MBP (Level 1) to Augmentation Arm (MBP with weekly VCP; Level 2)ExperimentalPhase 1: This arm includes participants in HMI + MBP (Level 1) who do not respond to treatment by week 5. The Augmentation Arm consists of MBP with weekly VCP (Level 2). Participants will have access to unlimited MBP and will be able to schedule weekly, 30-45 minute video chat with the same therapist. This intervention will serve as one of two conditions for participants who do not respond to MBP or VCP alone by week 5.
Receives: Behavioral: Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy; Behavioral: High Monetary Incentive (HMI)
Phase 1: HMI + MBP (Level 1) to Minimal Augmentation (MBP with monthly VCP; Level 2)ExperimentalPhase 1: This arm includes participants in HMI + MBP (Level 1) who do not respond to treatment by week 5. The Minimal Augmentation arm consists of MBP with monthly VCP (Level 2). Patients have access to unlimited MBP and once a month, 30-45 minute video chat with the same therapist. This intervention will serve as one of two conditions for participants who do not respond to MBP or VCP alone by week 5.
Receives: Behavioral: Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy; Behavioral: High Monetary Incentive (HMI)
Phase 1: LMAI + VCP (Level 1) to Augmentation Arm (MBP with weekly VCP; Level 2)ExperimentalPhase 1: This arm includes participants in LMAI + VCP (Level 1) who do not respond to treatment by week 5. The Augmentation Arm consists of MBP with weekly VCP (Level 2). Participants will have access to unlimited MBP and will be able to schedule weekly, 30-45 minute video chat with the same therapist. This intervention will serve as one of two conditions for participants who do not respond to MBP or VCP alone by week 5.
Receives: Behavioral: Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy; Behavioral: Low Monetary and Alternative Incentive (LMAI)
Phase 1: LMAI + VCP (Level 1) to Switch Arm (MBP with monthly VCP; Level 2)ExperimentalPhase 1: This arm includes participants in LMAI + VCP (Level 1) who do not respond to treatment by week 5. The Switch Arm consists of MBP with monthly VCP (Level 2). Patients have access to unlimited MBP and once a month, 30-45 minute video chat with the same therapist. This intervention will serve as one of two conditions for participants who do not respond to MBP or VCP alone by week 5.
Receives: Behavioral: Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy; Behavioral: Low Monetary and Alternative Incentive (LMAI)
Phase 1: LMAI + MBP (Level 1) to Augmentation Arm (MBP with weekly VCP; Level 2)ExperimentalPhase 1: This arm includes participants in LMAI + MBP (Level 1) who do not respond to treatment by week 5. The Augmentation Arm consists of MBP with weekly VCP (Level 2). Participants will have access to unlimited MBP and will be able to schedule weekly, 30-45 minute video chat with the same therapist. This intervention will serve as one of two conditions for participants who do not respond to MBP or VCP alone by week 5.
Receives: Behavioral: Message-Based Psychotherapy with Weekly Video-Chat Psychotherapy; Behavioral: Low Monetary and Alternative Incentive (LMAI)
Phase 1: LMAI + MBP (Level 1) to Minimal Augmentation (MBP with monthly VCP; Level 2)ExperimentalPhase 1: This arm includes participants in LMAI + MBP (Level 1) who do not respond to treatment by week 5. The Minimal Augmentation arm consists of MBP with monthly VCP (Level 2). Patients have access to unlimited MBP and once a month, 30-45 minute video chat with the same therapist. This intervention will serve as one of two conditions for participants who do not respond to MBP or VCP alone by week 5.
Receives: Behavioral: Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy; Behavioral: Low Monetary and Alternative Incentive (LMAI)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Neuro-QOL - Ability to Participate in Social Roles and Activities

    Neuro-Quality of Life v1.0 (Neuro-QOL). The Neuro-QOL Ability to Participate in Social Roles and Activities short form item bank is an 8-item patient-rated measure of social functioning. Items focus on difficulty participating in social, family, and work activities, and are rated on a 1 to 5 scale for a total score between 8 and 40. Neuro-QOL scores were transformed into t-scores per the scoring manual; after transformation, total scores range from 24.1 to 60.2. Transformed scores are reported. Higher scores indicate less difficulty participating in social roles and activities. The Neuro-QOL was not distributed in Phase 1.

    Measured: Change from Baseline Neuro-QOL at 6 weeks and 12 weeks after treatment starts

  2. Change in Patient Health Questionnaire (PHQ-9)

    The Patient Health Questionnaire-9 (PHQ-9) consists of 9 depression items and one disability item. Each time is associated with a Diagnostic and Statistical Manual (DMS) symptom of depression, which the participant rates whether or not they have experienced the symptom over the last two weeks, with severity rating of 0-3. It is one of the few measures that is brief (it takes less than one minute to give) and has been found to have excellent sensitivity to change over time. Total scores range from 0-27, with higher scores indicating greater severity of depression.

    Measured: Change from Baseline PHQ-9 at 6 weeks and 12 weeks after treatment starts

Secondary outcomes (1)
  1. Change in Generalized Anxiety Disorder (GAD-7)

    To assess for co-occurring anxiety, we will use the Generalized Anxiety Disorder-7 (GAD-7), a 7- item screener for generalized anxiety disorder (GAD). Participants rate on a scale of 0-3 how much they have experienced symptoms of GAD in the last two weeks. Total scores range from 0 to 21, with higher scores indicating greater severity of anxiety. The scale is a valid screener for GAD.

    Measured: Change from Baseline GAD-7 at 6 weeks and 12 weeks after treatment starts

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Aug 2020
  2. Study start2 Mar 2020
  3. Primary completion14 Jan 2024
  4. Study completion14 Jan 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Sequential
Model description
Phase 1 will test the effectiveness of two forms of participant retention methods into a SMART (sequential, multiple assignment, randomized). In Phase 1, participants (n=200) will be randomized to an incentive level and then randomized to treatment arms. Phase 2 (n=1000) will be the subsequent SMART design comparing message-based psychotherapy (MBP) to video-chat psychotherapy (VCP) in level 1 and for those who do not respond to care after 6 weeks, those participants will be randomized to either MBP+monthly VCP or MBP+weekly VCP. Arms/Interventions have been adjusted to align with the results for the Phase 2 SMART.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
1,184 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04513080
Sponsor's protocol ID
STUDY00010391
Status last verified
Oct 2025
First submitted
9 Aug 2020
Last updated
30 Oct 2025
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Quantitative data is available upon reasonable request with a fully executed Data Use Agreement with Talkspace.

Publications

  • Pullmann MD, Rouvere J, Raue PJ, Griffith Fillipo IR, Mosser BA, Heagerty PJ, Fridling-Cook N, Padmanabhan A, Hull TD, Arean PA. Message-Based vs Video-Based Psychotherapy for Depression: A Randomized Clinical Trial. JAMA Netw Open. 2025 Oct 1;8(10):e2540065. doi: 10.1001/jamanetworkopen.2025.40065.

    PubMed 41165707
  • Arean P, Hull D, Pullmann MD, Heagerty PJ. Protocol for a sequential, multiple assignment, randomised trial to test the effectiveness of message-based psychotherapy for depression compared with telepsychotherapy. BMJ Open. 2021 Nov 2;11(11):e046958. doi: 10.1136/bmjopen-2020-046958.

    PubMed 34728440

Questions about this trial

What is this clinical trial studying?

A study testing Video-Chat Psychotherapy (VCP), Message-Based Psychotherapy (MBP) and Message-Based Psychotherapy with Monthly Video-Chat Psychotherapy in people with Study Adherence and Depressive Disorder, run by Talkspace at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 30 Oct 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Neuro-QOL - Ability to Participate in Social Roles and Activities (time frame: Change from Baseline Neuro-QOL at 6 weeks and 12 weeks after treatment starts). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04513080, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in